Comparison of Cisatracurium and Succinylcholine on Hemodynamic Changes during and after Electroconvulsive Therapy

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Anesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, School of Medicine AND Students Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: The succinylcholine as a muscle relaxant is used in patients undergoing electroconvulsive therapy; so far, cisatracurium has not been used routinely and any study has not been done on it. Only limited use of cisatracurium has been reported in the literature. The aim of this study was to compare the changes in heart rate and blood pressure induced by succinylcholine and cisatracurium in patients who are undergoing electroconvulsive therapy.Methods: This clinical trial study was randomized double-blinded without controls. The study included 68 patients who were candidates for receiving electroconvulsive therapy. Using convenience sampling method, the patients were divided into two equal groups. Randomly, each group received one drugs (cisatracurium or succinylcholine). The collected data were analyzed using independent t and chi-square tests.Findings: The mean duration of seizures, spontaneous respiration recovery time since the cessation of seizure, duration of seizure to full consciousness, residence time of recovery were significantly different between the two treatment groups (P < 0.05 for all). As, the mean duration of seizures was more in cisatracurium group (38.02 ± 8.16 s) compared to succinylcholine group (29.87 ± 5.23 s); but, spontaneous respiration recovery time since the cessation of seizure, duration of seizure to full consciousness, residence time of recovery more in succinylcholine group.Conclusion: Cisatracurium is established as an intermediate-acting muscle relaxant with intermediate effect duration. Using low dose of cisatracurium, compared to succinylcholine, tends to shorter mean time to spontaneous respiration with much less complications after electroconvulsive therapy; it seems that cisatracurium can be a good alternative for succinylcholine in electric convulsive therapy.

Keywords

References

  1. Miller RD, Eriksson LI, Fleisher LA, Wiener-Kronish JP, Cohen NH. Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier/Saunders; 2015.
  2. Holden C. A guarded endorsement for shock therapy. Science 1985; 228(4707): 1510-1.
  3. Rasmussen KG, Sampson SM, Rummans TA. Electroconvulsive therapy and newer modalities for the treatment of medication-refractory mental illness. Mayo Clin Proc 2002; 77(6): 552-6.
  4. Potter WZ, Rudorfer MV. Electroconvulsive therapy-a modern medical procedure. N Engl J Med 1993; 328(12): 882-3.
  5. Sadock BJ, Sadock VA. Kaplan & Sadock's Comprehensive textbook of psychiatry. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000. p. 489-91.
  6. Hacettepe Üniversitesi Hastaneleri - Anesteziyoloji ve Reanimasyon AD, Ankara.
  7. Hicks FG. ECT Modified by Atracurium. Convuls Ther 1987; 3(1): 54-9.
  8. Holmberg G, Thesleff S. Succinyl-choline-iodide as a muscular relaxant in electroshock therapy. Am J Psychiatry 1952; 108(11): 842-6.
  9. Tolmie JD, Joyce TH, Mitchell GD. Succinylcholine danger in the burned patient. Anesthesiology 1967; 28(2): 467-70.
  10. Mazze RI, Escue HM, Houston JB. Hyperkalemia and cardiovascular collapse following administration of succinylcholine to the traumatized patient. Anesthesiology 1969; 31(6): 540-7.
  11. Stevenson PH, Birch AA. Succinylcholine-induced hyperkalemia in a patient with a closed head injury. Anesthesiology 1979; 51(1): 89-90.
  12. Stone WA, Beach TP, Hamelberg W. Succinylcholine-danger in the spinal-cord-injured patient. Anesthesiology 1970; 32(2): 168-9.
  13. Tobey RE. Paraplegia, succinylcholine and cardiac arrest. Anesthesiology 1970; 32(4): 359-64.
  14. Tobey RE, Jacobsen PM, Kahle CT, Clubb RJ, Dean MA. The serum potassium response to muscle relaxants in neural injury. Anesthesiology 1972; 37(3): 332-7.
  15. Gronert GA, Theye RA. Effect of succinylcholine on skeletal muscle with immobilization atrophy. Anesthesiology 1974; 40(3): 268-71.
  16. Sarubin J, Gebert E. Serum potassium rise following depolarizing muscle relaxants in immobilized patients (author's transl). Anaesthesist 1981; 30(5): 246-50.
  17. Consensus conference. Electroconvulsive therapy. JAMA 1985; 254(15): 2103-8.
  18. Thomas ET. Circulatory collapse following succinylcholine: report of a case. Anesth Analg 1969; 48(3): 333-7.
  19. Marco LA, Randels PM. Succinylcholine drug interactions during electroconvulsive therapy. Biol Psychiatry 1979; 14(2): 433-45.
  20. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999; 36(1): 27-40.
  21. Bryson HM, Faulds D. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Drugs 1997; 53(5): 848-66.
  22. Belmont MR, Lien CA, Quessy S, Abou-Donia MM, Abalos A, Eppich L, et al. The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology 1995; 82(5): 1139-45.
  23. Pinard AM, Donati F, Martineau R, Denault AY, Taillefer J, Carrier M. Magnesium potentiates neuromuscular blockade with cisatracurium during cardiac surgery. Can J Anaesth 2003; 50(2): 172-8.
  24. Mirinejad M, Azarfarin R, Asl AA. Cisatracurium in cardiac surgery-continuous infusion vs. bolus administration. Middle East J Anaesthesiol 2007; 19(3): 563-72.
  25. Dear GJ, Harrelson JC, Jones AE, Johnson TE, Pleasance S. Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 1995; 9(14): 1457-64.
  26. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995; 58(2): 132-42.
  27. Weindlmayr-Goettel M, Kress HG, Hammerschmidt F, Nigrovic V. In vitro degradation of atracurium and cisatracurium at pH 7.4 and 37 degrees C depends on the composition of the incubating solutions. Br J Anaesth 1998; 81(3): 409-14.
  28. Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996; 83(5): 1065-71.
  29. Kheirabadi G, Vafaei M, Attari A. Intravenous ketamine therapy vs. Electroconvulsive therapy in depressive cases. J Isfahan Med Sch 2012; 29(163): 1289-97. [In Persian].
  30. Bozkurt A, Barcin C, Isintas M, Ak M, Erdem M, Ozmenler KN. Changes in heart rate variability before and after ECT in the treatment of resistant major depressive disorder. Isr J Psychiatry Relat Sci 2013; 50(1): 40-6.
Journal of Isfahan Medical School
Volume 34, Issue 395 - Serial Number 395
July and August 2016
Pages 963-970

Files

History

  • Receive Date: 21 May 2016
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics